Piper Sandler lowered the firm’s price target on Myriad Genetics (MYGN) to $11.50 from $14 following quarterly results. The firm keeps a ...
BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad ...
Myriad Genetics, Inc. MYGN reported fourth-quarter 2024 adjusted earnings of 3 cents per share, which came in line with the ...
We recently published a list of Top 8 Trending AI News Updates Investors Should Not Miss. In this article, we are going to ...
StockStory.org on MSN6d
Why Myriad Genetics (MYGN) Shares Are Plunging TodayShares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported ...
SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi ...
New York State Common Retirement Fund boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by ...
Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P.
In trading on Thursday, shares of Myriad Genetics, Inc. (Symbol: MYGN) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $11.12 per share. By ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback